- Pulse Biosciences is set to report quarterly results for the September 2026 period on November 5, with analysts expecting a loss of $0.35 per share and materially higher revenue than in the same quarter a year earlier.
- The mix of a forecasted loss alongside stronger sales expectations puts the focus on how efficiently Pulse Biosciences is converting early procedure demand into a scalable commercial model.
- This raises the question of how the investment narrative for Pulse Biosciences might shift as investors weigh expected revenue growth against continued losses.
Scan beyond Pulse Biosciences and compare its setup with hand-picked medtech peers in our 34 healthcare AI stocks positioned around similar early-stage revenue stories and ongoing losses.
Pulse Biosciences Investment Narrative Recap
To hold Pulse Biosciences, you need to believe its nanosecond PFA platform grows from limited launches and trials into a routine tool in thyroid and cardiac care. The near term hinge is proof that early procedure demand can cover a heavy cost base. The expected September quarter loss, paired with stronger sales, does not materially change that equation yet.
The biggest swing factor over the next year remains clinical and commercial traction for nPulse Vybrance thyroid procedures and the cardiac programs. The key risk is simple. Operating expenses are high against modest revenue. Any slowdown in procedure adoption, reimbursement progress, or IDE timelines could keep losses large and extend the cash burn story.
Without fresh operational announcements tied to this print, the most relevant context remains the ongoing rollout of the nPulse Vybrance system and related thyroid nodule work. Your focus into November 5 sits on whether reported procedures and console placements support the idea that benign thyroid ablation can become a meaningful line of business rather than just a clinical curiosity.
The same earnings release also links back to the cardiac opportunity, including the nPulse cardiac clamp and 360 catheter programs in atrial fibrillation. Investors are watching for any update on trial enrollment, regulatory steps, or feasibility data that might tighten timelines. Progress here strengthens the long term revenue story, while delays would keep Pulse Biosciences more dependent on a still early thyroid franchise.
What The Long Range Pulse Biosciences Forecast Implies
Pulse Biosciences' story now hinges on how the long range forecasts line up with the near term losses investors are watching into the November report. Analysts are effectively mapping a path from heavy current cash use and limited sales to a small but positive earnings pool several years out, and the gap between those endpoints is what you need to judge.
The stock analysis report assumes a very large annual revenue growth rate of 218.5% over the next three years. That pace is tied to expectations that today’s small revenue base could scale quickly as more thyroid and cardiac procedures come through the nPulse platforms. For anyone tracking Pulse Biosciences, that projected expansion is less about fine tuned forecasting and more about the belief that these first commercial and trial sites can translate into a visibly broader installed base.
On profitability, the same report takes current earnings of a loss of US$80.1 million and builds a bridge to forecast consensus earnings of US$4.8 million by 2029. That move from deeply negative to modestly positive profit implies an earnings increase of about US$84.9 million over that period. In plain terms, the thesis requires both a sharp improvement in margins and a shift from heavy spending ahead of revenue to a more balanced cost structure as utilization improves.
Under those assumptions, analysts are also using an October 2029 forecast horizon to anchor their numbers. That year becomes the reference point for the modelled profit margin of 12.6% and the implied P/E multiple used in the valuation work. For readers, the key question is whether a 2029 earnings profile of US$4.8 million on revenue of US$38.3 million feels realistic, given what Pulse Biosciences is showing so far on console placements, procedure counts, and regulatory progress.
Pulse Biosciences' narrative projects US$38.3 million revenue and US$4.8 million earnings by 2029. This setup uses a very large 218.5% yearly revenue growth rate and assumes earnings move from a loss of US$80.1 million today to a profit of US$4.8 million, an earnings increase of about US$84.9 million.
Uncover why Pulse Biosciences' fair value indicates a 19% potential upside to its current price that could narrow quickly.
Exploring Other Perspectives
For a very different angle on Pulse Biosciences, the most optimistic analysts lean hard into the cardiac catalyst. They were modeling revenue of US$53.5 million and earnings of US$6.6 million by 2029, compared with the consensus of US$38.3 million and US$4.8 million. Both views pre date this earnings report, so you should expect opinions to evolve once fresh numbers land.
Explore another Pulse Biosciences fair value estimate, including one that suggests as much as 19% upside from the current price.
Reach Your Own Conclusion
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider doing your own research and forming independent views.
- A great starting point for your Pulse Biosciences research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
- See our latest analysis for Pulse Biosciences. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Pulse Biosciences' overall financial health at a glance.
Looking For More Investment Ideas Beyond Pulse Biosciences?
If the Pulse Biosciences setup has you thinking about position sizing, risk and upside across the rest of your watchlist, it can help to line it up against other opportunities with clear hooks and different return profiles.
- Seek potential mispricings in stronger businesses by comparing Pulse Biosciences with a 35 high quality undervalued stocks that combine solid fundamentals with more mature cash generation.
- If capital preservation matters most, balance a position in Pulse Biosciences with a 30 resilient stocks with low risk scores that score well on financial resilience and lower volatility characteristics.
- Prefer hunting for earlier stories with healthier foundations, rather than only following consensus picks, by scanning a 19 high quality undiscovered gems that pair quieter coverage with robust balance sheets and earnings quality.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com